David K. Lee
David K. Lee (born January 14, 1982) is an American businessman. He has held various executive positions in major pharmaceutical and biotechnology companies[1] and as of 2018 has been the CEO of Servier Pharmaceuticals.
Career[edit]
David K. Lee is a graduate of Harvard College and Harvard Business School. He has worked for Novartis and Baxalta before leading the global Oncology and Rare Disease franchises of Shire plc.[2] In 2018, he brokered the $2.4B deal to sell Shire's oncology assets to Laboratoires Servier to become the wholly-owned U.S. subsidiary, Servier Pharmaceuticals, to which he was named CEO.[3]
In 2020, he brokered the deal for Servier Pharmaceuticals to acquire the oncology assets of Agios Pharmaceuticals for $2B.[4]
References[edit]
- ↑ "Pharm Exec's Emerging Pharma Leaders 2020". Pharmaceutical Executive. Retrieved 2020-06-08.
- ↑ "Servier picks Shire executive to run U.S. business being built out of deal for Shire's oncology unit". FiercePharma. Retrieved 2018-07-20.
- ↑ "French drug maker Servier sets up US headquarters in Seaport". Boston Globe. Retrieved 2019-05-09.
- ↑ "Once aiming to double oncology pipeline, Servier's US branch touts rapid pace in building its foothold in the space". Endpoints News. Retrieved 2021-01-12.
This article "David K. Lee" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:David K. Lee. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
